HealthpointCapital, the leading private equity firm focused exclusively on musculoskeletal healthcare, today announced the acquisition of a majority stake in ImmersiveTouch, Inc. ("ImmersiveTouch" or the "Company"). ImmersiveTouch's ImmersiveView™ platform is a patented, proprietary Virtual Reality (VR) and Augmented Reality (AR) software solution for surgical planning, navigation and patient-customized surgical guides. Currently focused on facial and t

QT Imaging Holdings, Inc. (OTCQB:QTIH), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce its latest image reconstruction software update release, version 4.4.0, which delivers a substantial reduction in the QTscan™ image processing time, improving user throughput and overall efficiency. The software update was developed leveraging NVIDIA’s L40 GPU, powered by the Ada Lovelace architecture.

Tivic Health® Systems, Inc, a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study visits in the Optimization Study for its patent pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Initial findings reinforce the importance of personalization for therapeutic efficacy. Tivic expects to release the study results later this year. The study was conducted by The Fei

Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, today launched the PolyphonicTM AI Fund for Surgery to help develop AI solutions that solve challenges before, during, and after surgery. Joined by a coalition of companies including NVIDIA and Amazon Web Services (AWS), the initiative builds on the company’s work to advance AI that will help redefine modern surgical practices and improve patient outcomes. The Polyphonic AI Fund for Surgery

MellingMedical announced today a new strategic relationship with Zynex Medical, an industry pioneer in non-invasive medical devices for pain management and rehabilitation. The collaboration leverages MellingMedical's status as an SBA-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB) to bring Zynex's innovative pain management solutions to federal healthcare providers serving America's military personnel, DoD and veterans. "While we offer a wide range o

GE HealthCare today announced that the U.S. Food and Drug Administration (FDA) has approved an updated label for its positron emission tomography (PET) imaging agent VizamylTM (flutemetamol F 18 injection) for beta-amyloid detection. The revised label, effective immediately, expands the indications for use, enables quantitative analysis of Vizamyl scans, and removes significant previous limitations such as monitoring patient response to anti-amyloid therapy. Up to now, amyloid

Exactech, a global medical device technology leader, announced the first surgery using the new Alteon® Short Tapered Wedge Hip Stem. The procedure was performed by Mark Schinsky, MD, with The American Hip Institute & Orthopedic Specialists in Chicago. For every total hip replacement, my goal as a surgeon is to reconstruct a mechanically stable hip joint with implants that fit the patient's anatomical needs," said Dr. Schinsky. "The Alteon Short Tapere

Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), today announced that it has reached the first enrollment milestone in the CORCINCH-HF pivotal trial evaluating the AccuCinch® Transcatheter Left Ventricular Restoration System in patients with heart failure with reduced ejection fraction (HFrEF). Six-month follow-up data on these 250 patients will support the company’s Premarket Approval (PMA) submission to the

Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine – with one of their key intentions being the development and research of innovative total body PET/CT technology.i This effort is expected to explore new clinical pathways and help enhance patient outcomes through innovative imaging solutions. “PET/CT has revolutionized the way we understand and treat disease by allowing us to visual

CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, announced today that it has received Investigational Testing Authorization (ITA) from Health Canada to conduct the STRIDE trial, a clinical study evaluating CereVasc's eShunt System as a treatment for normal pressure hydrocephalus (NPH). The trial will evaluate the safety and effectiveness of the eShunt System versus the current standard of care, the ventriculo-peritone